Back

Elevated levels of the incretin hormone PYY are associated with cardiovascular events

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Predicting cardio-renal-metabolic disease (2) Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Martin Berger

RWTH University Hospital Aachen, Aachen (Germany)

6 More presentations in this session

Presentation thumbnail
Coronary inflammation predicts cardiovascular risk in the absence of standard modifiable risk factors (SMuRFs): the ORFAN study
Doctor L. Eveson (Oxford, GB)
Abstract Slides
Presentation thumbnail
Global cardiovascular risk prediction model in the Cuban population
Professor S. Lewington (Oxford, GB)
Abstract Slides
Presentation thumbnail
Sex specific serum uric acid is associated with complex coronary artery disease and cardiovascular outcome following percutaneous coronary intervention-a single center registry
Doctor Y. Moshkovits (Petah Tikva, IL)
Abstract Slides
Presentation thumbnail
The prognostic value of ECG parameters for 20-year cardiovascular risk and incremental improvement of SCORE2-based prediction modelling: the ATTICA cohort study (2002–2022)
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Life’s Essential 8 and SCORE2 for cardiovascular risk prediction in a middle‐aged general population: the Akershus Cardiac Examination 1950 Study
Doctor H. Ihle-Hansen (Oslo, NO)
Abstract Slides

Access the full session

Session thumbnail
Predicting cardio-renal-metabolic disease (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Is GLP-1 insufficiency a coronary risk factor? - a multicenter observational study, BOREAS-CAD2
27 August 2021
thumbnail
Congress Presentation
Bariatric surgery is associated with lower risk of acute cardiovascular events in patients with obesity and hypertrophic cardiomyopathy
27 August 2021
thumbnail
Congress Presentation
Heart rate and cardiovascular outcomes with and without beta-blocker in post-mi patients: a pre-specified analysis of the ABYSS trial.
1 September 2025
thumbnail
Congress Presentation
The cardiac sympathetic co-transmitter neuropeptide-Y is pro-arrhythmic in human cardiomyocytes by lengthening activation-recovery interval
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources